These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 22332191

  • 1. Failure of natalizumab to prevent relapses in neuromyelitis optica.
    Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O, Neuromyelitis Optica Study Group.
    Arch Neurol; 2012 Feb; 69(2):239-45. PubMed ID: 22332191
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population.
    Smith CH, Waubant E, Langer-Gould A.
    J Neuroophthalmol; 2009 Jun; 29(2):104-6. PubMed ID: 19491632
    [Abstract] [Full Text] [Related]

  • 8. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab.
    Kitley J, Evangelou N, Küker W, Jacob A, Leite MI, Palace J.
    J Neurol Sci; 2014 Apr 15; 339(1-2):223-5. PubMed ID: 24576801
    [Abstract] [Full Text] [Related]

  • 9. [Treatment and clinical management of patients with neuromyelitis optica and anti-aquaporin 4 antibody].
    Ochi H.
    Brain Nerve; 2010 Sep 15; 62(9):945-52. PubMed ID: 20844305
    [Abstract] [Full Text] [Related]

  • 10. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA.
    Arch Neurol; 2008 Nov 15; 65(11):1443-8. PubMed ID: 18779415
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
    Arnal-Garcia C, García-Montero MR, Málaga I, Millán-Pascual J, Oliva-Nacarino P, Ramió-Torrentà L, Oreja-Guevara C.
    Eur J Paediatr Neurol; 2013 Jan 15; 17(1):50-4. PubMed ID: 23021975
    [Abstract] [Full Text] [Related]

  • 12. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.
    Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T, Gold R.
    JAMA Neurol; 2013 Mar 01; 70(3):394-7. PubMed ID: 23358868
    [Abstract] [Full Text] [Related]

  • 13. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
    Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, Rommer P, Kleiter I, Stich O, Reuss R, Rauer S, Zettl UK, Wandinger KP, Melms A, Aktas O, Kristoferitsch W, Wildemann B.
    J Neurol Sci; 2011 Jul 15; 306(1-2):82-90. PubMed ID: 21550068
    [Abstract] [Full Text] [Related]

  • 14. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM.
    Lancet Neurol; 2013 Jun 15; 12(6):554-62. PubMed ID: 23623397
    [Abstract] [Full Text] [Related]

  • 15. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ.
    JAMA Neurol; 2013 Sep 01; 70(9):1110-7. PubMed ID: 23897062
    [Abstract] [Full Text] [Related]

  • 16. Interferon-beta(1b) treatment in neuromyelitis optica.
    Tanaka M, Tanaka K, Komori M.
    Eur Neurol; 2009 Sep 01; 62(3):167-70. PubMed ID: 19590215
    [Abstract] [Full Text] [Related]

  • 17. The rescue effect of plasma exchange for neuromyelitis optica.
    Wang KC, Wang SJ, Lee CL, Chen SY, Tsai CP.
    J Clin Neurosci; 2011 Jan 01; 18(1):43-6. PubMed ID: 20888238
    [Abstract] [Full Text] [Related]

  • 18. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.
    Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Pittock SJ.
    Arch Neurol; 2009 Sep 01; 66(9):1164-7. PubMed ID: 19752309
    [Abstract] [Full Text] [Related]

  • 19. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
    Prosperini L, Giannì C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, Gasperini C.
    Mult Scler; 2012 Jan 01; 18(1):64-71. PubMed ID: 21828195
    [Abstract] [Full Text] [Related]

  • 20. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
    Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, Le Mauff B.
    J Neurol Sci; 2012 Mar 15; 314(1-2):138-42. PubMed ID: 22050952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.